FR2940289B1 - Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas - Google Patents

Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas

Info

Publication number
FR2940289B1
FR2940289B1 FR0807426A FR0807426A FR2940289B1 FR 2940289 B1 FR2940289 B1 FR 2940289B1 FR 0807426 A FR0807426 A FR 0807426A FR 0807426 A FR0807426 A FR 0807426A FR 2940289 B1 FR2940289 B1 FR 2940289B1
Authority
FR
France
Prior art keywords
amino
treatment
pancreatic cancer
hydroxyquinoline class
class derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0807426A
Other languages
English (en)
Other versions
FR2940289A1 (fr
Inventor
Jean Louis Kraus
Olivier Blin
Frederic Champavere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biopharmed
Original Assignee
Biopharmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0807426A priority Critical patent/FR2940289B1/fr
Application filed by Biopharmed filed Critical Biopharmed
Priority to EP09805949A priority patent/EP2382193A1/fr
Priority to CA2748124A priority patent/CA2748124A1/fr
Priority to AU2009332511A priority patent/AU2009332511A1/en
Priority to US13/140,514 priority patent/US20110251238A1/en
Priority to PCT/IB2009/055950 priority patent/WO2010073235A1/fr
Priority to CN2009801519893A priority patent/CN102300847A/zh
Publication of FR2940289A1 publication Critical patent/FR2940289A1/fr
Application granted granted Critical
Publication of FR2940289B1 publication Critical patent/FR2940289B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/24Oxygen atoms attached in position 8
    • C07D215/26Alcohols; Ethers thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0807426A 2008-12-23 2008-12-23 Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas Expired - Fee Related FR2940289B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0807426A FR2940289B1 (fr) 2008-12-23 2008-12-23 Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas
CA2748124A CA2748124A1 (fr) 2008-12-23 2009-12-23 Compositions agonistes de ppar et procedes d'utilisation
AU2009332511A AU2009332511A1 (en) 2008-12-23 2009-12-23 PPAR agonist compositions and methods of use
US13/140,514 US20110251238A1 (en) 2008-12-23 2009-12-23 Ppar agonist compositions and methods of use
EP09805949A EP2382193A1 (fr) 2008-12-23 2009-12-23 Compositions agonistes de ppar et procédés d'utilisation
PCT/IB2009/055950 WO2010073235A1 (fr) 2008-12-23 2009-12-23 Compositions agonistes de ppar et procédés d'utilisation
CN2009801519893A CN102300847A (zh) 2008-12-23 2009-12-23 Ppar激动剂组合物及其使用方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0807426A FR2940289B1 (fr) 2008-12-23 2008-12-23 Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas

Publications (2)

Publication Number Publication Date
FR2940289A1 FR2940289A1 (fr) 2010-06-25
FR2940289B1 true FR2940289B1 (fr) 2014-09-12

Family

ID=40785273

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0807426A Expired - Fee Related FR2940289B1 (fr) 2008-12-23 2008-12-23 Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas

Country Status (7)

Country Link
US (1) US20110251238A1 (fr)
EP (1) EP2382193A1 (fr)
CN (1) CN102300847A (fr)
AU (1) AU2009332511A1 (fr)
CA (1) CA2748124A1 (fr)
FR (1) FR2940289B1 (fr)
WO (1) WO2010073235A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201208775D0 (en) 2012-05-18 2012-07-04 Uni I Oslo Chemical compounds
CN104903494B (zh) * 2012-09-21 2017-11-03 瑞奥可塞恩探索集团有限公司 用于电解液体的电池
GB201320506D0 (en) 2013-11-26 2014-01-01 Uni I Oslo Cyclic amino compounds for the use in the treatment of cardiac disorders
WO2018059437A1 (fr) * 2016-09-27 2018-04-05 Beigene, Ltd. Traitement de cancers à l'aide d'une combinaison comprenant des inhibiteurs de parp
CN109843857B (zh) 2016-10-05 2023-01-06 米托布里奇公司 Ppar激动剂化合物的结晶和盐形式
CN106822901A (zh) * 2016-11-01 2017-06-13 中山大学 过氧化物酶体增殖剂激活受体α对肉毒碱棕榈酰基转移酶1C的直接调控作用及抗肿瘤应用
CN110164511A (zh) * 2019-05-08 2019-08-23 重庆科技学院 一种快速筛选PPARα/δ双重激动剂的方法
WO2024040132A2 (fr) * 2022-08-16 2024-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Interactions synergiques pour traitement anticancéreux amélioré

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827599A1 (fr) * 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
EP1565185A4 (fr) * 2002-11-07 2011-01-05 Technion Res & Dev Foundation Chelateurs du fer et compositions pharmaceutiques les renfermant
RS50670B (sr) * 2004-05-21 2010-06-30 Novartis Vaccines And Diagnostics Inc. Supstitucionisani derivati hinolina kao mitotički kinezinski inhibitori
WO2007146824A2 (fr) * 2006-06-08 2007-12-21 Array Biopharma Inc. Quinolines et méthodes d'utilisation
FR2913976B1 (fr) * 2007-03-23 2013-04-26 Biopharmed Derives de la classe des hydroxyquinoleines aminees pour le traitement de cancers.
WO2009140215A2 (fr) * 2008-05-11 2009-11-19 Geraghty, Erin Procédé pour traiter des infections bactériennes résistant au médicament et d'autres infections par du clioquinol, de la phanquinone et des composés apparentés

Also Published As

Publication number Publication date
US20110251238A1 (en) 2011-10-13
FR2940289A1 (fr) 2010-06-25
EP2382193A1 (fr) 2011-11-02
WO2010073235A1 (fr) 2010-07-01
AU2009332511A1 (en) 2011-07-14
CN102300847A (zh) 2011-12-28
CA2748124A1 (fr) 2010-07-01

Similar Documents

Publication Publication Date Title
FR2940289B1 (fr) Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas
ATE453635T1 (de) C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
FR2925339B1 (fr) Medicament pour le traitement du cancer du pancreas
HK1138850A1 (en) Quinoline derivatives for the treatment of inflammatory diseases
ZA201006868B (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
EP2063897A4 (fr) Inhibiteurs de kinases utiles pour le traitement de maladies prolifératives
EP2063896A4 (fr) Inhibiteurs de la kinase utiles dans le traitement de maladies prolifératives
FR2932478B1 (fr) Composes utiles pour le traitement des cancers.
DK2478907T3 (da) Sammensætninger til behandling af kræft
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
IL196470A (en) Antagonist antibody for cancer treatment
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
HK1130208A1 (en) Alpha-msh derivatives for the treatment of photodermatoses -msh
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
NO20091266L (no) Fremgangsmåter for administrering av langvarige hypoglykemiske midler
ATE502944T1 (de) 2-amino-5,7-dihydro-6h-pyrroloä3,4- düpyrimidinderivate als hsp-90-inhibitoren zur behandlung von krebs
DE602006010449D1 (de) Behandlung von geflügel zwecks reduzierung der futon ascites
BRPI0822129A2 (pt) Inibidores de aldh-2c no tratamento de vício.
DK2099446T3 (da) Fremgangsmåde til behandling af inflammatorisk tarmsygdom
BR112012003653A2 (pt) "método de tratar o câncer."
FR2913976B1 (fr) Derives de la classe des hydroxyquinoleines aminees pour le traitement de cancers.

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20150831